Factors of influence on acute skin toxicity of breast cancer patients treated with standard three-dimensional conformal radiotherapy (3D-CRT) after breast conserving surgery (BCS)
详细信息 查看全文
- 作者：Uta Kraus-Tiefenbacher (1)
Andreas Sfintizky (1)
Grit Welzel (1)
Anna Simeonova (1)
Elena Sperk (1)
Kerstin Siebenlist (1)
Sabine Mai (1)
Frederik Wenz (1) - 关键词：Skin toxicity ; Breast cancer ; External beam radiotherapy
- 刊名：Radiation Oncology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：7
- 期：1
- 全文大小：203KB
- 参考文献：1. Fisher B, Anderson S, Bryant J, / et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. / N Engl J Med 2002, 347:1233-241. CrossRef
2. Lopez E, Nunez MI, Guerrero MR, / et al.: Breast cancer acute radiotherapy morbidity evaluated by different scoring systems. / Breast Canc Res Treat 2002, 73:127-34. CrossRef
3. Porock D, Kristjanson L: Skin reactions during chemotherapy for breast cancer: the use and impact of topical agents and dressings. / Eur J Cancer Care 1998, 8:143-53. CrossRef
4. Fisher J, Scott C, Stevens R, / et al.: Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-3. / Int J Radiat Oncol Biol Phys 2000, 48:1307-310. CrossRef
5. Harsolia A, Kestin L, Grills I, / et al.: Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. / Int J Radiat Oncol Bio lPhys 2007, 68:1375-380. CrossRef
6. Pignol J, Olivotto I, Rakovitch E, / et al.: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. / J Clin Oncol 2008, 26:2085-092. CrossRef
7. Back M, Guerrieri M, Wratten C, / et al.: Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer. / Clin Oncol 2004, 16:12-6. CrossRef
8. Formenti SC, Gidea-Addeo D, Goldberg JD, / et al.: Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. / J Clin Oncol 2007, 25:2236-242. CrossRef
9. Jalali R, Malde R, Bhutani R, / et al.: Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy. / Breast 2008, 17:64-0. CrossRef
10. Fernando IN, Ford HT, Powles TJ, / et al.: Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital. / J Clin Oncol (R Coll Radiol) 1996, 8:226-33. CrossRef
11. Becker-Schiebe M, Mengs U, Schaefer M, / et al.: Topical use of a silymarin-based preparation to prevent radiodermatitis: results of a prospective study in breast cancer patients. / Strahlenther Onkol 2011, 187:485-91. CrossRef
12. Pinnix C, Perkins GH, Strom EA, / et al.: Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. / Int J Radiat Oncol Biol Phys 2011. Epub ahead of print
13. Vicini FA, Sharpe M, Kestin L, / et al.: Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. / Int J Radiat Oncol Biol Phys 2002, 54:1336-344. CrossRef
14. Freedman GM, Anderson PR, Li J, / et al.: Intensity modulated radiation therapy (IMR) decreases acute skin toxicity for women receiving radiation for breast cancer. / Am J Clin Oncol 2006, 29:66-0. CrossRef
15. Donovan EM, Johnson U, Shentall G, / et al.: Evaluation of compensation in breast radiotherapy: A planning study using multiple static fields. / Int J Radiat Oncol Biol Phys 2000, 46:1307-310. CrossRef
16. Wells M, Macmillan M, Raab G, / et al.: Doesaquaeous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomized controlled trial. / Radiother Oncol 2004, 73:153-62. CrossRef
17. Bostrom A, Lindman H, Swarting C, / et al.: Potent corticosteroid cream (mometasonefuroate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. / Radiother Oncol 2001, 59:257-65. CrossRef
18. Mai SK, Welzel G, Haegele V, / et al.: The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. / Radiat Oncol 2007, 21:30-. CrossRef
19. Schmuth W, Wimmer MA, Hofer S, / et al.: Topical corticosteroid therapy for acute radiation dermatitis: A prospective, randomized, double-blind study. / Br J Dermatology 2002, 146:983-91. CrossRef
20. Shukla PN, Gairola M, Mohanti BK, / et al.: Prophylactic beclomethason spray to the skin during postoperative radiotherapy of carcinoma breast: A prospective randomized study. / Indian Journal of Cancer 2006, 4:180-84. CrossRef
21. Porock D, Kristjanson L: Skin reactions during radiotherapy for breast cancer: the use and impact of topical agents and dressings. / Eur J Cancer Care 1999, 8:142-53. CrossRef
22. Taylor ME, Perez CA, Halverson KJ, / et al.: Factors influencing cosmetic results after conservation therapy for breast cancer. / Int J Radiat Oncol Biol Phys 1995, 31:753-64. CrossRef
23. Wazer DE, Morr J, Erban JK, / et al.: The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. / Cancer 1997, 80:732-40. CrossRef
24. Fowble B, Fein DA, Hanlon AL, / et al.: The impact of tamoxifen on breast recurrence, cosmesis, comlications and survival in estrogen receptor-positivealry-stage breast cancer. / Int J Radiat Oncol Biol Phys 1996, 35:669-77. CrossRef
25. Rayan G, Dawson LA, Bezjak A, / et al.: Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy. / Int J Radiat Oncol Biol Phys 2003, 55:154-61. CrossRef
26. Belkacémi Y, Gligorov J, Ozsahin M, / et al.: Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. / Ann Oncol 2008, 19:1110-116. CrossRef
27. Azria D, Belkacémi Y, Romieu G, / et al.: Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomized trial. / Lancet Oncol 2010, 11:258-65. CrossRef
28. Pommier P, Gomez F, Sunyach MP, / et al.: Phase 3 randomized trial of Calendula officinalis compared to trolamine for prevention of acute dermatitis during irradiation for breast cancer. / J Clin Oncol 2004, 22:1447-453. CrossRef
29. Twardella D, Popanda O, Helmbold I, / et al.: Personal characteristics, therapy modalities and individual DNA repair capacity as prede factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. / Radiother Oncol 2003, 69:145.153. CrossRef
30. Fiets WE, Van Helvoit RP, Nortier JWR, / et al.: Acute toxicity of concurrent adjvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients: a prospective, comparative, non-randomized study. / Eur J Cancer 2003, 39:1081-088. CrossRef - 作者单位：Uta Kraus-Tiefenbacher (1)
Andreas Sfintizky (1)
Grit Welzel (1)
Anna Simeonova (1)
Elena Sperk (1)
Kerstin Siebenlist (1)
Sabine Mai (1)
Frederik Wenz (1)
1. Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, 68167, Mannheim, Germany
文摘
Purpose/Objectives Standard 3D-CRT after BCS may cause skin toxicity with a wide range of intensity including acute effects like erythema or late effects. In order to reduce these side effects it is mandatory to identify potential factors of influence in breast cancer patients undergoing standard three-dimensional conformal radiation therapy (3D-CRT) of the breast and modern systemic therapy. Materials/Methods Between 2006 and 2010 a total of 211 breast cancer patients (median age 52,4 years, range 24-7) after BCS consecutively treated in our institution with 3D-CRT (50 Gy whole breast photon radiotherapy followed by 16 Gy electron boost to the tumorbed) were evaluated with special focus on documented skin toxicity at the end of the 50 Gy-course. Standardized photodocumentation of the treated breast was done in each patient lying on the linac table with arms elevated. Skin toxicity was documented according to the common toxicity criteria (CTC)-score. Potential influencing factors were classified in three groups: patient-specific (smoking, age, breast size, body mass index = BMI, allergies), tumor-specific (tumorsize) and treatment-specific factors (antihormonal therapy with tamoxifen or aromatase inhibitors, chemotherapy). Uni- and multivariate statistical analyses were done using IBM SPSS version 19. Results After 50 Gy 3D-CRT to the whole breast 28.9% of all 211 patients had no erythema, 62.2% showed erythema grade 1 (G1) and 8.5% erythema grade 2. None of the patients had grade 3/4 (G3/4) erythema. In univariate analyses a significant influence or trend on the development of acute skin toxicities (erythema G0 versus G1 versus G2) was observed for larger breast volumes (p=0,004), smoking during radiation therapy (p=0,064) and absence of allergies (p=0,014) as well as larger tumorsize (p=0,009) and antihormonal therapy (p=0.005). Neither patient age, BMI nor choice of chemotherapy showed any significant effect on higher grade toxicity. In the multivariate analysis, factors associated with higher grade skin toxicity were larger breast target volume (p=0,003), smoking (p=0,034) and absence of allergies (p=0,002). Conclusion Patients treated in this study showed less objectively documented skin toxicity after 50 Gy 3D-CRT compared to similar patient cohorts. Factors associated with higher grade skin toxicity were smoking during 3D-CRT, absence of allergies and larger breast volumes.